Jonathan H Schatz

Associate Professor

  • 999 Citations
If you made any changes in Pure, your changes will be visible here soon.

Fingerprint Fingerprint is based on mining the text of the experts' scientific documents to create an index of weighted terms, which defines the key subjects of each individual researcher.

  • 10 Similar Profiles
Neoplasms Medicine & Life Sciences
Lymphoma Medicine & Life Sciences
Follicular Lymphoma Medicine & Life Sciences
Phosphotransferases Medicine & Life Sciences
Lymphoma, Large B-Cell, Diffuse Medicine & Life Sciences
Non-Hodgkin's Lymphoma Medicine & Life Sciences
T-Cell Lymphoma Medicine & Life Sciences
Therapeutics Medicine & Life Sciences

Network Recent external collaboration on country level. Dive into details by clicking on the dots.

Projects 2014 2019

Anaplastic Large-Cell Lymphoma

Research Output 2006 2019

  • 999 Citations
  • 26 Article
  • 1 Comment/debate
  • 1 Editorial

Complications of Intrathecal Chemotherapy in Adults: Single-Institution Experience in 109 Consecutive Patients

Byrnes, D. M., Vargas, F., Dermarkarian, C., Kahn, R., Kwon, D., Hurley, J., Schatz, J. H. & Masetti, R., Jan 1 2019, In : Journal of Oncology. 2019, 4047617.

Research output: Contribution to journalArticle

Open Access
Drug Therapy
Burkitt Lymphoma
Central Nervous System
Nervous System

Short survival and frequent transformation in extranodal marginal zone lymphoma with multiple mucosal sites presentation

Alderuccio, J. P., Zhao, W., Desai, A., Ramdial, J., Gallastegui, N., Kimble, E., De La Fuente, M. I., Husnain, M., Rosenblatt, J. D., Alencar, A. J., Schatz, J. H., Moskowitz, C., Chapman-Fredricks, J., Vega, F., Reis, I. & Lossos, I., Jan 1 2019, In : American Journal of Hematology.

Research output: Contribution to journalArticle

Disease-Free Survival
Marginal Zone B-Cell Lymphoma

EIF4A inhibition: Ready for primetime?

Cunningham, T. A., Chapman, E. & Schatz, J. H., Oct 1 2018, In : Oncotarget. 9, 85, p. 35515-35516 2 p.

Research output: Contribution to journalEditorial

Drug Discovery
2 Citations (Scopus)

Phase 2 Open-Label Study of Bortezomib, Cladribine, and Rituximab in Advanced, Newly Diagnosed, and Relapsed/Refractory Mantle-Cell and Indolent Lymphomas

Puvvada, S. D., Guillen-Rodriguez, J., Kumar, A., Inclán, L., Heard, K., Rivera, X. I., Anwer, F., Schatz, J. H., Mahadevan, D. & Persky, D. O., Jan 1 2018, In : Clinical Lymphoma, Myeloma and Leukemia. 18, 1, p. 58-64 7 p.

Research output: Contribution to journalArticle

Mantle-Cell Lymphoma
Non-Hodgkin's Lymphoma
Disease-Free Survival
5 Citations (Scopus)

Statins enhance efficacy of venetoclax in blood cancers

Lee, J. S., Roberts, A., Juarez, D., Vo, T. T. T., Bhatt, S., Herzog, L. O., Mallya, S., Bellin, R. J., Agarwal, S. K., Salem, A. H., Xu, T., Jia, J., Li, L., Hanna, J. R., Davids, M. S., Fleischman, A. G., O'Brien, S., Lam, L. T., Leverson, J. D., Letai, A. & 2 othersSchatz, J. H. & Fruman, D. A., Jun 13 2018, In : Science Translational Medicine. 10, 445, eaaq1240.

Research output: Contribution to journalArticle

Hydroxymethylglutaryl-CoA Reductase Inhibitors
Protein Prenylation